Lorin K Johnson Net Worth

The estimated Net Worth of Lorin K Johnson is at least $597 dollars as of 8 January 2020. Lorin Johnson owns over 8,524 units of 9 Meters Biopharma stock worth over $597 and over the last 6 years Lorin sold NMTR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lorin Johnson NMTR stock SEC Form 4 insiders trading

Lorin has made over 1 trades of the 9 Meters Biopharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Lorin bought 8,524 units of NMTR stock worth $35,034 on 8 January 2020.

The largest trade Lorin's ever made was buying 8,524 units of 9 Meters Biopharma stock on 8 January 2020 worth over $35,034. On average, Lorin trades about 501 units every 0 days since 2018. As of 8 January 2020 Lorin still owns at least 8,524 units of 9 Meters Biopharma stock.

You can see the complete history of Lorin Johnson stock trades at the bottom of the page.

What's Lorin Johnson's mailing address?

Lorin's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 4509 CREEDMOOR ROAD, SUITE 201, RALEIGH, NC, 27612.

Insiders trading at 9 Meters Biopharma

Over the last 4 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.

What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Complete history of Lorin Johnson stock trades at Edesa Biotech and 9 Meters Biopharma

9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include:

• John Temperato,
  Pres, CEO & Director
• Dr. Patrick H. Griffin,
  Chief Medical Officer
• Edward J. Sitar CPA, CPA,
  Chief Financial Officer
• Sarah Liu M.B.A.,
  Chief Commercial Officer
• Albert J. Medwar M.B.A., MBA,
  Sr. VP of Investor Relations & Corp. Communications
• Bethany Sensenig C.M.A., M.B.A.,
  Chief Financial Officer
• Dr. Nir Barak M.D.,
  Sr. VP of Scientific Affairs
• Dr. Elena Verdu M.D., Ph.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Ciaran P. Kelly M.D.,
  Clinical & Scientific Advisor and Consultant
• Joseph A. Murray,
  Clinical & Scientific Advisor and Consultant
• Dr. Peter H. R. Green M.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Nir Barak,
  Sr. VP of Scientific Affairs
• Jerry Gardner,
  Head of Clinical Strategy
• Sireesh Appajosyula Pharm.D.,
  Sr. VP of Corp. Devel. & Operations
• Samantha Ventimiglia,
  Director
• Bethany Sensenig,
  Chief Financial Officer
• John Temperato,
  Chief Executive Officer
• Edward J Sitar,
  Chief Financial Officer
• Lorin K Johnson,
  Director
• Israel Gp Ltd.Orbi Med Isra...,
  
• Nissim Darvish,
  Director
• Sandeep Laumas,
  Director
• Mark A Sirgo,
  Director
• Saira Ramasastry,
  Director
• Roy Proujansky,
  Director
• Yehuda Michael Rice,
  Director
• Jay P. Madan,
  President
• Anthony E Iii Maida,
  Director
• Michael T. Constantino,
  Director